Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.
about
Second-line treatment of recurrent HNSCC: tumor debulking in combination with high-dose-rate brachytherapy and a simultaneous cetuximab-paclitaxel protocol.ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.Salivary miRNA panel to detect HPV-positive and HPV-negative head and neck cancer patients.Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012.
P2860
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 April 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.
@en
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.
@nl
type
label
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.
@en
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.
@nl
prefLabel
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.
@en
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.
@nl
P2093
P2860
P356
P1476
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab.
@en
P2093
Akshar N Patel
Janice M Mehnert
P2860
P356
10.4137/CMENT.S5129
P577
2012-04-03T00:00:00Z